Actinium Pharmaceuticals, Inc. (ATNM) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 PARK AVE., 23RD FLOOR
NEW YORK, NY 10017
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments47,99872,90476,677108,91077,82963,560
Cash and cash equivalent47,99872,90476,677108,91077,82963,560
Restricted cash and investments    698392439
Prepaid expense 1,2151,2451,360749935860
Other current assets 168357226   
Other undisclosed current assets   58559366
Total current assets:49,38174,50678,263110,94279,74964,925
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization102030358140
Operating lease, right-of-use asset1,7541,6852,2892,341241579
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization295364550604340312
Restricted cash and investments335324313302  
Other undisclosed noncurrent assets      441
Total noncurrent assets:2,3942,3933,1823,2506391,472
TOTAL ASSETS:51,77576,89981,445114,19280,38866,397
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:7,2477,568   4,340
Other undisclosed accounts payable and accrued liabilities7,2477,568   4,340
Debt11117,96410,1345,59785
Other undisclosed current liabilities7115695304941,243342
Total current liabilities:7,9698,1488,49410,6286,8404,767
Noncurrent Liabilities
Long-term debt and lease obligation  919   
Finance lease, liability  919   
Liabilities, other than long-term debt35,97235,98436,553   
Deferred revenue35,00035,00035,000   
Operating lease, liability9729841,553   
Other undisclosed noncurrent liabilities    37,0833311
Total noncurrent liabilities:35,97235,99336,57237,0833311
Total liabilities:43,94144,14145,06647,7116,8435,078
Equity
Equity, attributable to parent7,83432,75836,37966,48173,54561,319
Common stock313128262218
Additional paid in capital417,536408,553373,934355,220329,271292,275
Accumulated other comprehensive loss(20)     
Accumulated deficit(409,713)(375,826)(337,583)(288,765)(255,748)(230,974)
Total equity:7,83432,75836,37966,48173,54561,319
TOTAL LIABILITIES AND EQUITY:51,77576,89981,445114,19280,38866,397

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues90 811,0301,144 
Sublease income    1,0301,144 
Other income   100   
Cost of revenue     (900) 
Gross profit:90 811,030244 
Operating expenses(36,337)(42,121)(52,001)(35,134)(26,108)(22,393)
Other undisclosed operating income     900 
Operating loss:(36,247)(42,121)(51,920)(34,104)(24,964)(22,393)
Nonoperating income2,3603,8783,1021,087190178
Investment income, nonoperating2,3603,878    
Interest and debt expense (1)(2) (2)(9) 
Loss from continuing operations:(33,888)(38,245)(48,818)(33,019)(24,783)(22,215)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(24,783)(22,215)
Other undisclosed net income     9 
Net loss:(33,888)(38,245)(48,818)(33,019)(24,774)(22,215)
Other undisclosed net income attributable to parent 12 2  
Net loss attributable to parent:(33,887)(38,243)(48,818)(33,017)(24,774)(22,215)
Other undisclosed net loss available to common stockholders, basic      (1)
Net loss available to common stockholders, diluted:(33,887)(38,243)(48,818)(33,017)(24,774)(22,216)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(33,888)(38,245)(48,818)(33,019)(24,774)(22,215)
Comprehensive loss:(33,888)(38,245)(48,818)(33,019)(24,774)(22,215)
Other undisclosed comprehensive loss, net of tax, attributable to parent(19)     
Comprehensive loss, net of tax, attributable to parent:(33,907)(38,245)(48,818)(33,019)(24,774)(22,215)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: